Last updated: 2026-09-05 13:44:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Onconetix, Inc. (ONCO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.02, with a market capitalization of $2.95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.59 to $209.50. This page covers its latest market performance, valuation, price trends and company information.
$2.95M | |
$0.74 | |
$90,950.00 | |
$0.59 | |
$0.74 | |
3.22M | |
-- | |
-- | |
$209.50 | |
$0.59 | |
-- | |
-- |
Onconetix, Inc. (ONCO) last closed at $0.74 as of 2026-09-05 00:00:00, unchanged from the previous close of $0.74.
During the latest regular trading session, ONCO traded between $0.59 and $90,950.00, with a volume of 3.22M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Onconetix, Inc. (ONCO) moved from $0.60 to $1.02, representing a gain of 70.17% ($0.42).
The stock traded between $0.70 and $1.04 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.07 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.2%
ONCO is currently trading at $1.02, placing it 0.2% of the way from its 52-week low of $0.59 to its 52-week high of $209.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Onconetix, Inc. (ONCO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.